Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ...

Related Keywords

Chau Cheng ,Exchange Commission ,Neurology Clinical Development Updates ,Due To Roivant Sciences Ltd ,General Clinical Development Updates ,Endocrinology Clinical Development Updates ,Immunovant Inc ,Clinical Development Updates ,Thyroid Eye Disease ,Insulin Growth Factor ,Fiscal Fourth Quarter Ended March ,Fiscal Year Ended March ,Private Securities Litigation Reform Act ,Annual Report ,Roivant Sciences ,